When treating patients with Helicobacter pylori infection who have previously been exposed to macrolides, which treatment approach does the American College of Gastroenterology (ACG) recommend?
The presence of significant levels of antibiotic resistance, along with treatment failure, has rendered conventional first-line therapy for the treatment of Helicobacter pylori infections unsuitable in many areas.
The patients in a recent Phase 3 trial evaluating three different first-line treatments for H. pylori infection were randomized to one of three treatments: vonoprazan with amoxicillin (dual P-CAB), vonoprazan with amoxicillin and clarithromycin (triple P-CAB), or lansoprazole with amoxicillin and clarithromycin (triple P-CAB) (triple lansoprazole). As opposed to lansoprazole, which of the following statements better characterizes the P-CAB regimens: